Beam Therapeutics annual free cash flow
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Free Cash Flow (FCF) History (BEAM)
Beam Therapeutics reported −$360.0M in free cash flow for fiscal 2025, a decrease of $3.9M from the previous fiscal year, with a free cash flow margin of −257.65%.
View full Beam Therapeutics company overviewBeam Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$360.0M | −$3.9M | — | −257.65% |
| 2024 | 2024-12-31 | −$356.2M | −$173.3M | — | −560.77% |
| 2023 | 2023-12-31 | −$182.9M | −$156.5M | — | −48.43% |
| 2022 | 2022-12-31 | −$26.4M | $86.7M | — | −43.37% |
| 2021 | 2021-12-31 | −$113.1M | −$981,000 | — | −218.11% |
| 2020 | 2020-12-31 | −$112.1M | −$27.6M | — | −467075.00% |
| 2019 | 2019-12-31 | −$84.5M | — | — | −469561.11% |
Beam Therapeutics quarterly free cash flow
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$68.5M | $11.1M | — | −13981.63% |
| Q1 2026 | 2026-03-31 | −$130.7M | −$23.8M | — | −411.95% |
| Q4 2025 | 2025-12-31 | −$87.0M | −$7.7M | — | −76.26% |
| Q3 2025 | 2025-09-30 | −$86.5M | $3.2M | — | −891.83% |
| Q2 2025 | 2025-06-30 | −$79.6M | $5.4M | — | −940.07% |
| Q1 2025 | 2025-03-31 | −$106.9M | −$4.8M | — | −1431.71% |
| Q4 2024 | 2024-12-31 | −$79.3M | −$210.8M | — | −263.86% |
| Q3 2024 | 2024-09-30 | −$89.7M | $8.0M | — | −628.65% |
| Q2 2024 | 2024-06-30 | −$85.0M | $15.9M | — | −721.80% |
| Q1 2024 | 2024-03-31 | −$102.2M | $13.6M | — | −1379.01% |
| Q4 2023 | 2023-12-31 | $131.5M | $208.9M | — | +41.58% |
| Q3 2023 | 2023-09-30 | −$97.7M | −$11.4M | — | −568.44% |
| Q2 2023 | 2023-06-30 | −$100.8M | −$26.9M | — | −501.33% |
| Q1 2023 | 2023-03-31 | −$115.8M | −$327.1M | — | −478.49% |
| Q4 2022 | 2022-12-31 | −$77.5M | −$65.9M | — | −386.54% |
| Q3 2022 | 2022-09-30 | −$86.3M | −$83.5M | — | −546.13% |
| Q2 2022 | 2022-06-30 | −$73.9M | −$25.2M | — | −443.91% |
| Q1 2022 | 2022-03-31 | $211.2M | $261.3M | — | +2505.11% |
| Q4 2021 | 2021-12-31 | −$11.5M | $20.9M | — | −22.59% |
| Q3 2021 | 2021-09-30 | −$2.8M | $21.3M | — | −363.43% |
| Q2 2021 | 2021-06-30 | −$48.7M | −$23.5M | — | −811850.00% |
| Q1 2021 | 2021-03-31 | −$50.1M | −$19.6M | — | −834266.67% |
| Q4 2020 | 2020-12-31 | −$32.4M | −$12.5M | — | −540383.33% |
| Q3 2020 | 2020-09-30 | −$24.0M | −$5.6M | — | −400533.33% |
| Q2 2020 | 2020-06-30 | −$25.2M | −$7.3M | — | −420066.67% |
| Q1 2020 | 2020-03-31 | −$30.4M | −$2.2M | — | −507316.67% |
| Q4 2019 | 2019-12-31 | −$20.0M | — | — | — |
| Q3 2019 | 2019-09-30 | −$18.4M | — | — | −306850.00% |
| Q2 2019 | 2019-06-30 | −$17.9M | — | — | −298983.33% |
| Q1 2019 | 2019-03-31 | −$28.2M | — | — | — |
Beam Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$112.1M to −$360.0M, a net decrease of $247.9M. Beam Therapeutics's latest reported quarter, Q2 2026, generated −$68.5M in free cash flow, an increase of $11.1M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...
